Search results for "RCT"

showing 10 items of 1934 documents

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Isolated Dysphagia in a Patient with Medial Medullary Infarction – Effects of Evidence-Based Dysphagia Therapy: A Case Report

2021

Medial medullary infarction (MMI) is a vascular occlusion in the medulla oblongata leading to certain constellations of neurological symptoms and seriously affecting the patient. Effective evidence-based treatment of severe dysphagia as sole symptom of MMI has not yet been reported. This case study aims to report successful effects of evidence-based therapy based on findings of dysphagia symptoms and pathophysiology of swallowing by flexible endoscopic evaluation of swallowing (FEES) in severe isolated dysphagia after MMI. FEES was performed to evaluate swallowing pathophysiology and dysphagia symptoms in a 57-year-old male with severe dysphagia after MMI. On the basis of FEES findings, sim…

medicine.medical_specialtyEvidence-based practiceMedullary cavitydysphagiamedicine.medical_treatmentInfarctionVascular occlusionlcsh:RC346-429Swallowingflexible endoscopic evaluation of swallowingotorhinolaryngologic diseasesmedicinecase reportmedial medullary infarctionlcsh:Neurology. Diseases of the nervous systemRehabilitationbusiness.industryevidence-based therapyCase Series − General Neurologymedicine.diseaseDysphagiaPathophysiologySurgerydysphagia therapyNeurology (clinical)medicine.symptombusinessCase Reports in Neurology
researchProduct

Cross-country skiing and the risk of acute myocardial infarction: A prospective cohort study

2019

medicine.medical_specialtyExercise ToleranceCross countryEpidemiologybusiness.industryMyocardial InfarctionMEDLINEmedicine.diseaseRisk FactorsSkiingEmergency medicinemedicineHumansProspective StudiesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessProspective cohort studyEuropean Journal of Preventive Cardiology
researchProduct

Platelet Function Tests and Coronary Heart Disease

1984

It is well known that the formation of a platelet aggregate is the first step in an arterial thrombotic process.

medicine.medical_specialtyFramingham Risk ScoreEndotheliumPlatelet aggregationbusiness.industryeducationmedicine.diseaseCoronary heart diseasestomatognathic diseasesmedicine.anatomical_structurePlatelet function testPlatelet adhesivenessInternal medicinemedicineCardiologyPlateletMyocardial infarctionbusiness
researchProduct

013 Pre-infarction angina and cardiovascular complications in non ST segment elevation myocardial infarction: Data from the RICO survey

2010

BackgroundThe presence of preinfarction angina (PIA) has been shown to confer cardioprotection after ST segment elevation myocardial infarction (MI). However, the impact of PIA in non ST segment elevation (NSTEMI) remains to be determined.Patients and MethodsFrom the obseRvatoire des Infarctus de Côte d’Or (RICO) survey, 1541 consecutive patients admitted in intensive care unit with a first NSTEMI were included in the study. Patients who experienced chest pain 1) and 30-day mortality were collected.ResultsAmong the 1541 patients included in the study, 693 patients presented PIA. Baseline clinical characteristics were similar for the 2 groups. There was no significant difference for the GRAC…

medicine.medical_specialtyFramingham Risk Scorebusiness.industryInfarctionmedicine.diseaseChest painIntensive care unitlaw.inventionAnginalawHeart failureInternal medicinemedicineCardiologyST segmentMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Randomised clinical trials: a source of ethical dilemmas

2001

Clinical trials give rise to ethical dilemmas, especially in the acutely ill, but we take issue with two points raised in a recent comment on a specific acute myocardial infarction (AMI) trial. The commentators judged that the trial most likely could, and therefore should, have been terminated much earlier. By analysing the problem statistically we arrive at results that go against their intuitive judgment—they also see it as mandatory to update the patient Information sheet as trial results accrue and trends begin to emerge. In our view, interpreting subtle trends and borderline p-values must rest with data monitoring boards, not patients. Moreover, patients with AMI or in other medical em…

medicine.medical_specialtyHealth (social science)medicine.medical_treatmentAt the Coalface: Medical Ethics in PracticeTreatment outcomeMyocardial InfarctionAlternative medicineHospital mortalityResearch EthicsArts and Humanities (miscellaneous)Informed consentAngioplastymedicineHumansEthics MedicalThrombolytic TherapyHospital MortalityMyocardial infarctionIntensive care medicineRandomized Controlled Trials as TopicInformed Consentbusiness.industryPatient SelectionHealth PolicyAngioplastyCoronary Care Unitsmedicine.diseasehumanitiesClinical trialIssues ethics and legal aspectsTreatment OutcomeClinical researchEthics ClinicalData Interpretation StatisticalMedical emergencybusinessJournal of Medical Ethics
researchProduct

Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance

2012

Myocardial infarction is a major cause of death and disability worldwide. Myocardial infarction may represent a major catastrophic event leading to severe hemodynamic failure or sudden death or it may occur repeatedly in patients with established heart disease. In this context, the role of imaging techniques may become useful for the understanding of the determinants in a preclinical setting before acute coronary events, and for an accurate and correct diagnosis of myocardial infarction. Three-dimensional noninvasive imaging techniques, such as Cardiac CT (CCT) and Cardiac MR imaging (CMR) were widely developed in the last two decades. These imaging techniques may provide new insights into …

medicine.medical_specialtyHeart diseaseContext (language use)Coronary Artery DiseaseSudden deathInternal medicineMedicineHumanscardiovascular diseasesMyocardial infarctionPharmacologymedicine.diagnostic_testbusiness.industryCoronary StenosisElectrocardiography in myocardial infarctionMagnetic resonance imagingmedicine.diseaseCoronary arteriesMyocardial infarctionmedicine.anatomical_structurecardiovascular systemCardiologyRadiologyMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessMagnetic Resonance AngiographyTomography Emission-Computed
researchProduct

Electrochemical nano-immunosensing of effective cardiac biomarkers for acute myocardial infarction

2013

Abstract This review provides an overview of the various types of electrochemical immunosensors that have been developed for determination of cardiac biomarkers, along with significant advances over the last several years in related technologies. We also summarize the latest developments in the applications of electrochemical immunosensors in ultrasensitive detection of electroactive cardiac biomarkers.

medicine.medical_specialtyHeart diseasebiologyCardiac biomarkersbusiness.industrymedicine.diseaseTroponinAnalytical Chemistrychemistry.chemical_compoundMyoglobinchemistryInternal medicinemedicineCardiologybiology.proteinMyocardial infarctionbusinessSpectroscopyTrAC Trends in Analytical Chemistry
researchProduct

Treatment and Prophylaxis

1991

Following a stroke, the patient’s neurologic deficit may be most impressive, but his treatment and prognosis depend largely upon accompanying systemic disorders. Acute treatment, for instance, must take into consideration such things as cardiovascular disorders (myocardial infarction, valve defects, arrhythmias, hypertension), disorders of renal function, and diabetes mellitus. The early detection and treatment of such systemic problems can help to prevent complications that would be difficult to control later. Thus, in a patient with latent heart disease hypervolemic therapy with low molecular weight dextran may in fact elicit right heart failure and pulmonary edema instead of helping the …

medicine.medical_specialtyHeart diseasebusiness.industryCerebral infarctionRenal functionmedicine.diseasePulmonary edemaLow molecular weight dextranRight heart failureDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionbusiness
researchProduct

Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

2014

SummaryBackground A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). Aim To estimate the maximum-tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. Methods Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300–500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. Results Twenty-one patients were enrolled, inclu…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyPharmacokinetic analysisSurgeryPharmacokineticsInternal medicineHepatocellular carcinomaToxicitymedicineIdarubicinPharmacology (medical)Myocardial infarctionbusinessAdverse effectObjective responsemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct